-
Lecanemab Injection Approved for Marketing by China NMPA
2024-01-09
Recently, the Lecanemab Injection (trade name: 乐意保/Leqembi) of Eisai Inc. was approved for marketing by China NMPA through the priority review and approval procedures. It is indicated for the treatment of mild cognitive impairment and dementia caused by Alzheimer's disease.
-
China to further enhance medical treatment for critical pregnant women
2024-01-08
Starting this year, Chinese health authorities will launch an annual evaluation of the medical treatment services for women during the pregnant and perinatal period who are in critical conditions, according to the National Health Commission (NHC).
-
National health response teams capable of covering all provincial regions of China
2024-01-02
All provincial and 90 percent of municipal disease control centers have nucleic acid detection and virus isolation capabilities, Wang Hesheng, deputy head of the National Health Commission and chief of the National Disease Control and Prevention Administration, said during a press conference.
-
China accelerates development of county-level medical consortia
2024-01-02
The Chinese government has released a comprehensive set of guidelines to expedite the development of closely integrated medical and health consortia at the county level, with the intent of enhancing grassroots medical services.
-
Chinese hospitals continue to report falling trend in respiratory disease rates
2023-12-25
The overall volumes of people being diagnosed with and treated for respiratory diseases have continued to see a decreasing trend nationwide, a health official said on Sunday.
-
China sees occupational health improvements
2023-12-25
China has witnessed a continuing downward trend of occupational disease prevalence in the country, with a 40 percent decrease in newly diagnosed occupational disease cases between 2019 and 2022.
